Delivered-To: tjphuhs@gmail.com Received: by 2002:a05:622a:2b4e:b0:50f:b801:ff26 with SMTP id hb14csp2590954qtb; Tue, 12 May 2026 09:14:11 -0700 (PDT) X-Received: by 2002:a05:620a:1231:b0:90d:7196:2f95 with SMTP id af79cd13be357-90d71964364mr252005985a.19.1778602451278; Tue, 12 May 2026 09:14:11 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1778602451; cv=none; d=google.com; s=arc-20240605; b=jKqNZFFJJS1ss2ihFUJxdhHCqdqSFfNelD0H2IFqBNPfJhON8JZx5RCb11kyNNTj7r FQ6SX9l2uVI1m3Jrnq/diGGielN5aaHnZXZZZ7XDv43GT+vJ0uAjMn8cGJuE2GWtadiA SPCtwb2rHVoPhLu+9o+MHFevOFIdEl5SyXyQa+rB2SpDi2HvhOxTB2wRpnDCmvt5OMWx sr4NCIIOOmFLJuEuxzNmKDOE5YDLbEQLK4juMrJ6M3KrB6kBJyLz3SYkjNd/9oEEU8Yl qaIcoE3L90ii0OvtGQickIBWoG+8WlxzaXTXO4/LN2lYgh57+SLhMyP5bsRobAT2kApJ gXqQ== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=0s5P7V8ATILVFFMZirtK3IwOg8/rsJn1K7GbjRnKnvE=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=EPPmCDkqZVQkK/U747fMMEX74O77aKsODgx7Rlr6N/u7Syr0LAe4yCl1+/QvctVj5m uEEr5xk9J/iP52wVplEqRoKKuUEdD0kc4mekz5iOX/ROjdsJmqXXXziv9T05kTmMmr7a sBqtYUOZLx5F3nkc8cApMR+4msDSBycIamm/dchgx9HiwSn9/DxIc1lPOaIsiM+F+RIu 4BNHq4vQjY0URuNr3TJLR1A6CcdV/BcNdrbghGah5oDU+HhFWwAdNXuQ6JIcDZdoQO4K v65cb7di+JoVj2kUGw9Fdxmfp0FOpCPAT6rlPaIajemHRmLzYz7XK7P7QuZuNjLluGfM 4nKw==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=rnqlJCj8; dkim=pass header.i=@mailgun.org header.s=mg header.b=ejnWEW48; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 161.38.194.182 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from mg-194-182.static.mg-d0.substack.com (mg-194-182.static.mg-d0.substack.com. [161.38.194.182]) by mx.google.com with UTF8SMTPS id af79cd13be357-906a78cada1si1634403085a.385.2026.05.12.09.14.10 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Tue, 12 May 2026 09:14:11 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 161.38.194.182 as permitted sender) client-ip=161.38.194.182; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=rnqlJCj8; dkim=pass header.i=@mailgun.org header.s=mg header.b=ejnWEW48; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 161.38.194.182 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d0.substack.com; q=dns/txt; s=mailo; t=1778602450; x=1778609650; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=0s5P7V8ATILVFFMZirtK3IwOg8/rsJn1K7GbjRnKnvE=; b=rnqlJCj8YQ2ZS7Twz0ZOAOhMxdnf4ojc1S9bzBQ7v6oSOzXlptp73d3qdVnmXVUxzlKGgMsc6sKkXQZzevsBvZNG+MsAl4Z0icS+wRd7M7jhwZ2tVqeoGfge1YjfI+gAPxFYHcxcOXnxILCa2pX9EiOOaRHUAbuQyZktbrN5KZY= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1778602450; x=1778609650; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=0s5P7V8ATILVFFMZirtK3IwOg8/rsJn1K7GbjRnKnvE=; b=ejnWEW48uR6d/bPtoFklvapz6y3ir3czJvu3VBX1W4s5mr2Mm4IJIALPyTr9w05Lc8ueWR1ApAjWkygJ533u9UnKFBv5ltj+4WNlUfrUhSmZSplDXodoeUjXfoisKsbGteptIbRFiz/X6rRTgRkaUwP82iLjhZVPMXg2xrErWdA= X-Mailgun-Sid: WyJkZWU4NyIsInRqcGh1aHNAZ21haWwuY29tIiwiNjNhZjVkIl0= X-Feedback-Id: postmaster@mg-d0.substack.com:post:6148c7d8a45790427cda307f:mailgun Received: by a219ad7b3d6ca7de0999b283d34165076568f53c0d48a811e91d8a3e644d3d27 with HTTP id 6a0351d297e166ad8ad2899d; Tue, 12 May 2026 16:14:10 GMT X-Mailgun-Sending-Ip: 161.38.194.182 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="67e9e483af4652257f7d2fdc19d26f48cc109a9d336a8094dc3cdf175206" Subject: =?UTF-8?q?PCOS:_What_It_Actually_Is,_How_It=E2=80=99s_Managed_Now,_And_Th?= =?UTF-8?q?e_Peptide_Mechanisms_Worth_Watching?= From: Derek from Research Radar To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260512161359.3.8d5c67801145f0c7@mg-d0.substack.com> Date: Tue, 12 May 2026 16:13:59 +0000 Feedback-Id: post-197372111:cat-post:pub-3365367:substack Sender: Derek from Research Radar References: In-Reply-To: Reply-To: Derek from Research Radar List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1778602449988", "is_freemail": "true", "post_audience": "everyone", "post_id": "197372111", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --67e9e483af4652257f7d2fdc19d26f48cc109a9d336a8094dc3cdf175206 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/pcos-what-i= t-actually-is-how-its One of the most common conditions in women of reproductive age =E2=80=94 an= d one that happens to sit at the intersection of every major mechanism pept= ide research targets. Research and educational purposes only. Nothing in this piece is medical ad= vice. PCOS is a medical diagnosis that requires real clinical care =E2=80= =94 peptides discussed here are research tools, not treatments. If you have= PCOS or suspect you do, work with a clinician. What PCOS Actually Is Let=E2=80=99s start with the basics. Polycystic ovary syndrome (PCOS) is the most common hormonal disorder in wo= men of reproductive age =E2=80=94 affecting roughly 10 to 13 percent of wom= en globally. It=E2=80=99s not a single disease with a single cause. It=E2= =80=99s a complex, heterogeneous syndrome where three things tend to show u= p together: Irregular or absent ovulation, which leads to irregular periods and fertili= ty issues Hyperandrogenism =E2=80=94 excess androgens, the =E2=80=9Cmale=E2=80=9D hor= mones like testosterone. This is what drives the cosmetic stuff: acne, hirs= utism (unwanted hair growth in male-pattern areas), and androgenic hair los= s Polycystic ovarian morphology =E2=80=94 multiple small follicles on ultraso= und, or elevated anti-M=C3=BCllerian hormone (AMH) But the real story is bigger than the ovaries. PCOS is fundamentally a whole-body metabolic and endocrine condition. Most = patients also have insulin resistance, chronic low-grade inflammation, incr= eased risk of type 2 diabetes, obesity, sleep apnea, cardiovascular disease= , anxiety, depression, and endometrial cancer. It=E2=80=99s lifelong. The reproductive symptoms get most of the attention,= but the metabolic and psychological consequences extend well past the repr= oductive years. What Drives PCOS There are a few interconnected things going wrong at once. Understanding th= ese matters because every peptide mechanism we=E2=80=99ll discuss later tar= gets one of them. Genetics. There=E2=80=99s a strong hereditary component. In one study of fi= rst-degree relatives, 24 percent of mothers and 32 percent of sisters of PC= OS patients also had PCOS. Genome-wide association studies have identified = multiple risk genes involved in gonadotropin action, insulin signaling, and= androgen biosynthesis. Interestingly, male relatives can show metabolic fe= atures of PCOS too =E2=80=94 early-onset male-pattern baldness, insulin res= istance, type 2 diabetes =E2=80=94 suggesting this is a systemic genetic ri= sk, not just ovary-specific. Epigenetics and environment. The genetic background sets the stage, but env= ironmental factors trigger the actual disorder. Prenatal exposure to elevat= ed androgens, postnatal exposure to endocrine-disrupting chemicals (bisphen= ol A, certain pesticides, microplastics), poor diet, and sedentary lifestyl= e all alter gene expression in ways that drive the PCOS phenotype. Ovarian hyperandrogenism. This is the core issue. About 90 percent of PCOS = patients have it. The theca cells in the ovary make too much androgen, whic= h disrupts follicle maturation. Instead of one follicle maturing each cycle= and releasing an egg, multiple small follicles arrest at an immature stage= =2E That=E2=80=99s the =E2=80=9Cpolycystic= =E2=80=9D appearance on ultrasound=20= =E2=80=94 they aren=E2=80=99t cysts in the disease sense, they=E2=80=99re s= talled follicles. Insulin resistance and hyperinsulinemia. Insulin resistance is present in a= majority of PCOS patients =E2=80=94 even in lean ones, which surprises a l= ot of people. When cells stop responding properly to insulin, the pancreas = pumps out more to compensate. That elevated insulin does two damaging thing= s in PCOS: It directly stimulates the ovaries to make more androgens It suppresses the liver=E2=80=99s production of sex hormone-binding globuli= n (SHBG), which means more free testosterone is floating around unbound This is why fixing insulin resistance is one of the most important targets = in PCOS care. HPO axis dysfunction. The hypothalamic-pituitary-ovarian axis runs the show= on the hormonal side. In PCOS, gonadotropin-releasing hormone (GnRH) pulse= s too fast, which skews luteinizing hormone (LH) higher than follicle-stimu= lating hormone (FSH). That LH/FSH imbalance further drives ovarian androgen= production and impairs ovulation. Chronic low-grade inflammation. Adipose tissue =E2=80=94 especially viscera= l fat =E2=80=94 in PCOS pumps out inflammatory cytokines: TNF-alpha, IL-6, = IL-1-beta. The gut microbiome is also altered, with increased intestinal pe= rmeability contributing to systemic inflammation. That inflammation worsens= insulin resistance, increases ovarian androgen production, and impairs fol= licle development. It=E2=80=99s a feedback loop. Mitochondrial dysfunction. This is newer to the conversation but increasing= ly well-documented. Granulosa cells (the cells supporting the egg) in PCOS = show impaired mitochondrial function, elevated reactive oxygen species, and= reduced mitochondrial membrane potential. That energy failure in the ovary= contributes to follicle arrest and egg quality issues. How PCOS Is Currently Managed This is the conventional medicine approach, based on the 2023 international= evidence-based guideline. Knowing this matters because it=E2=80=99s the fo= undation that peptide research is being layered onto. Lifestyle modification. Always first-line, always non-negotiable. Diet (no = single =E2=80=9Cbest=E2=80=9D diet =E2=80=94 sustainable, individualized ma= tters more than the specific approach), 150-300 minutes of moderate exercis= e per week plus muscle-strengthening on two days, sleep, stress management.= Even modest weight loss (5-10 percent of body weight) can dramatically imp= rove symptoms and restore ovulation in some patients. Hormonal contraceptives. Combined oral contraceptives are first-line for ma= naging menstrual irregularities and androgen-driven symptoms like acne and = hirsutism. They protect the uterine lining from the cancer risk of unoppose= d estrogen, regulate cycles, and reduce androgens. Formulations with antian= drogenic progestins (drospirenone, dienogest) are preferred when hyperandro= genism is prominent. Spironolactone. An antiandrogen often added when oral contraceptives alone = don=E2=80=99t control hirsutism or acne. Dosing typically 50-200 mg/day. Ha= s fetal toxicity risk, so contraception is required. Metformin. The old workhorse. It improves insulin sensitivity. The current = guideline has cooled on metformin somewhat =E2=80=94 it=E2=80=99s not first= -line for weight loss or ovulation induction anymore, though it still has a= role in adolescents and lean patients with prediabetes or type 2 diabetes.= Maximum dose 2000 mg/day, extended-release preferred for tolerability. GLP-1 receptor agonists. This is where the field is shifting fast. Liraglut= ide, semaglutide, and exenatide are increasingly used off-label in PCOS. A = 2025 meta-analysis showed GLP-1 RAs significantly reduce fasting insulin, p= ost-glucose insulin response, and insulin resistance scores, plus they driv= e meaningful weight loss. Their mechanism hits multiple PCOS drivers at onc= e =E2=80=94 improving insulin sensitivity, reducing inflammation, and indir= ectly reducing ovarian androgen production. Critical note: pregnancy safety= data is lacking, so effective contraception is required for women of repro= ductive age. Inositol. Specifically myo-inositol and D-chiro-inositol in research. It=E2= =80=99s a second messenger that helps insulin signaling and FSH signaling a= t the cellular level. The evidence is modest =E2=80=94 possible improvement= in metabolic measures, but limited effects on ovulation or hirsutism. Low = risk of harm, so it shows up frequently as an adjunct. Letrozole. The first-line ovulation induction drug now (it overtook clomiph= ene). For PCOS patients trying to conceive who don=E2=80=99t ovulate on the= ir own, letrozole started day 3 of cycle, 2.5 mg titrated up to 7.5 mg as n= eeded. Bariatric surgery. For PCOS patients with severe obesity who haven=E2=80=99= t responded to other interventions. Often produces dramatic improvements in= insulin resistance, androgens, and ovulation. What=E2=80=99s missing from this picture: There=E2=80=99s no treatment that addresses the root genetic and epigenetic= drivers, no targeted way to fix ovarian mitochondrial dysfunction, no clea= n solution for the chronic inflammation piece, and limited tools for the ps= ychological burden. This is where peptide research gets interesting. Why PCOS Is A Peptide Research Target Here=E2=80=99s why this matters from a peptide research standpoint. The PCOS phenotype involves several mechanisms that overlap directly with w= hat peptides are known to influence: insulin sensitivity, chronic inflammat= ion, gut barrier integrity, mitochondrial function, HPO axis signaling, and= tissue repair. Almost every layer of PCOS pathophysiology has a peptide me= chanism that=E2=80=99s been studied for it in some context. That=E2=80=99s not a claim that any peptide treats PCOS. The point is that = the mechanisms PCOS depends on aren=E2=80=99t black boxes =E2=80=94 they=E2= =80=99re well-mapped pathways, and several peptides have research backing f= or influencing those exact pathways. Let=E2=80=99s walk through them. GLP-1 And Advanced Incretins This is the most clinically advanced and best-evidenced peptide class for P= COS, so we=E2=80=99ll start here. GLP-1 receptor agonists (semaglutide, liraglutide, exenatide). Discussed ab= ove as part of standard care. The mechanism in PCOS hits three pillars at o= nce: weight loss (reduces adipose-driven inflammation and improves insulin = sensitivity systemically), improved insulin sensitivity (lowers compensator= y hyperinsulinemia, which is what=E2=80=99s driving ovarian androgen produc= tion), and direct anti-inflammatory effects on multiple tissues. GLP-1/GIP dual agonists (tirzepatide). Tirzepatide adds GIP receptor agonis= m on top of GLP-1. In PCOS research and metabolic syndrome research more br= oadly, the addition of GIP signaling produces greater improvements in insul= in sensitivity and weight loss compared to GLP-1 alone. The mechanism: GIP = signaling enhances insulin sensitivity in adipose tissue and improves the m= etabolic flexibility of fat cells. GLP-1/GIP/glucagon triple agonist (retatrutide). Retatrutide adds glucagon = receptor agonism =E2=80=94 which, somewhat counterintuitively, increases en= ergy expenditure and accelerates fat breakdown for fuel. In a 2025 scoping = review, the triple agonist class produced the largest improvements in weigh= t loss and insulin sensitivity in PCOS-relevant research compared to GLP-1 = and dual agonists. Retatrutide is still pre-FDA approval but is moving thro= ugh trials. What the literature shows specifically for PCOS Significant reductions in fasting insulin and post-glucose insulin response Significant improvements in insulin resistance scores (HOMA-IR) Improvements in dysmenorrhea and ovarian morphology in some studies Weight loss substantially greater than with metformin What the literature shows is NOT changed by GLP-1 RAs alone Total and free testosterone (mostly unchanged in meta-analysis) DHEA-S, SHBG, free androgen index Hirsutism scores (modest at best) The honest interpretation: GLP-1 RAs are powerful tools for the metabolic s= ide of PCOS, but they don=E2=80=99t fully reverse the intrinsic ovarian hyp= erandrogenism. That confirms PCOS is fundamentally an ovarian disorder exac= erbated by metabolic dysfunction =E2=80=94 not the other way around. Weight= loss alone doesn=E2=80=99t fix everything, but it dramatically improves a = lot of it. BPC-157 And The Gut-Ovary Connection This is one of the more underrated angles in PCOS peptide research. The gut microbiome is altered in PCOS. There=E2=80=99s reduced microbial di= versity, increased intestinal permeability (=E2=80=9Dleaky gut=E2=80=9D), a= nd this is part of what drives systemic inflammation. That chronic low-grad= e inflammation worsens insulin resistance and ovarian androgen production. = Fix the gut, and you address one of the upstream amplifiers. BPC-157 (Body Protection Compound). A pentadecapeptide originally derived f= rom gastric juice. The mechanism is multimodal: it promotes gut lining repa= ir, reduces intestinal permeability, modulates the gut-brain axis, supports= angiogenesis, and has anti-inflammatory effects. In animal research, BPC-1= 57 has reversed leaky gut syndrome and restored multiple deranged molecular= pathways. It=E2=80=99s also been shown to influence dopaminergic signaling= , GABA activity, and serotonergic pathways =E2=80=94 which is relevant to t= he psychological symptoms in PCOS (anxiety, depression). Why this matters for PCOS: Gut barrier repair reduces endotoxin leakage and systemic inflammation, whi= ch improves insulin sensitivity The gut-brain axis effects are relevant to the mood and anxiety burden in P= COS The angiogenic and tissue repair properties may support ovarian tissue heal= th This is not a =E2=80=9CBPC-157 treats PCOS=E2=80=9D claim. It=E2=80=99s a = =E2=80=9Cthe upstream amplifier of inflammation in PCOS partially originate= s in the gut, and BPC-157 has research evidence for restoring gut barrier f= unction=E2=80=9D claim. KPV (lysine-proline-valine). A C-terminal tripeptide derived from alpha-MSH= =2E Potent anti-inflammatory, immune-mo= dulating, and antimicrobial activity,=20= particularly in the gut and skin. KPV suppresses inflammatory cytokines (TN= F-alpha, IL-6) which are the same cytokines elevated in PCOS adipose tissue= =2E Often stacked with BPC-157 for gut-= focused protocols. Relevant for the in= flammation arm of PCOS. Kisspeptin And The HPO Axis This is one of the most directly relevant peptide research areas for PCOS, = and it gets very little attention in mainstream peptide communities. Kisspeptin is a hypothalamic peptide encoded by the KISS1 gene. It=E2=80=99= s the master regulator of GnRH neurons =E2=80=94 meaning it=E2=80=99s upstr= eam of the entire reproductive hormone cascade. Without kisspeptin signalin= g, GnRH doesn=E2=80=99t pulse, LH and FSH don=E2=80=99t release properly, a= nd the ovaries don=E2=80=99t function. In PCOS, kisspeptin signaling is dysregulated. Higher kisspeptin tone contr= ibutes to the increased LH pulse frequency that drives ovarian androgen pro= duction. But here=E2=80=99s where it gets interesting: Research published in 2024-2026 has shown that kisspeptin, particularly in = local ovarian tissue, plays a different role from its central role =E2=80= =94 it improves local ovarian insulin resistance and protects mitochondrial= function in granulosa cells. What the recent research shows: Kisspeptin activates the PI3K/AKT/GLUT4 signaling pathway in ovarian granul= osa cells, improving local insulin sensitivity Kisspeptin reduces reactive oxygen species in granulosa cells and increases= mitochondrial membrane potential =E2=80=94 protecting energy production in= the cells that support egg development Antagonizing kisspeptin signaling worsens these parameters This is a fascinating duality: central (hypothalamic) kisspeptin dysregulat= ion drives parts of PCOS pathology, but peripheral (ovarian) kisspeptin app= ears to be protective. The therapeutic implication is complex =E2=80=94 you= can=E2=80=99t just turn kisspeptin up or down systemically. But it points = to kisspeptin signaling as a major research target, and selective modulator= s may be a future direction. For the curious: there are already kisspeptin antagonists being developed f= or hyperandrogenism and selective agonists being studied for hypogonadism. = PCOS is in between, and the research is genuinely active. Mitochondrial Peptides Mitochondrial dysfunction in ovarian granulosa cells is one of the more rec= ent additions to the PCOS pathophysiology picture, and it opens up a differ= ent category of peptide research. MOTS-c. A mitochondria-derived 16-amino acid peptide encoded by mitochondri= al 12S rRNA. It improves insulin sensitivity, increases mitochondrial effic= iency, and modulates metabolic signaling through AMPK activation. MOTS-c ha= s been studied for metabolic syndrome and aging-related metabolic decline. = There=E2=80=99s preliminary research suggesting reduced MOTS-c levels in ov= arian tissue may be relevant to PCOS pathology, though direct PCOS clinical= work is still early. The connection: PCOS granulosa cells show impaired mitochondrial function. = MOTS-c=E2=80=99s mechanism of restoring mitochondrial signaling and improvi= ng systemic insulin sensitivity overlaps directly with two major PCOS drive= rs. SS-31 (elamipretide). A mitochondrial membrane-stabilizing peptide that bin= ds cardiolipin. SS-31 protects mitochondria from oxidative damage and resto= res ATP production. While it hasn=E2=80=99t been formally studied in PCOS, = the rationale is straightforward =E2=80=94 PCOS granulosa cells have damage= d mitochondria with reduced membrane potential and elevated ROS, and SS-31 = is one of the most direct tools for that exact problem. Research models in = oocyte aging (which shares some features with PCOS-related egg quality issu= es) have shown SS-31 improves oocyte quality. Urolithin A. A postbiotic mitophagy inducer. UA promotes the clearance of d= amaged mitochondria and the building of new ones. There=E2=80=99s emerging = research suggesting that mitophagy dysfunction in granulosa cells contribut= es to PCOS, and UA=E2=80=99s mechanism of restoring mitophagy is mechanisti= cally relevant. None of these have completed PCOS-specific human trials. But mechanisticall= y, the mitochondrial peptide class is one of the more compelling research d= irections for the ovarian and metabolic dysfunction in PCOS. Other Peptides Worth Knowing About A few additional peptides with mechanisms that touch PCOS pathophysiology. Thymosin Alpha-1. Immune-modulating peptide. PCOS involves chronic low-grad= e inflammation and skewed immune signaling. While not a direct PCOS therapy= , the immune modulation may be relevant to the inflammation arm. GHK-Cu. Tripeptide-copper complex with anti-inflammatory, antioxidant, and = tissue repair effects. Skin-relevant applications connect to the cosmetic b= urden of PCOS (acne, hyperpigmentation, hair-related issues). Selank and Semax. Russian-developed cognitive peptides with anxiolytic and = BDNF-modulating effects respectively. PCOS has high prevalence of anxiety a= nd depression. These don=E2=80=99t address the underlying PCOS biology but = may have relevance for the psychological burden. Tesofensine. Not a peptide, but worth flagging =E2=80=94 it=E2=80=99s a tri= ple monoamine reuptake inhibitor in development for obesity that=E2=80=99s = showing strong weight loss data and may be relevant for PCOS patients who d= on=E2=80=99t tolerate GLP-1 agonists. The Honest Big Picture I want to be direct about what this all adds up to. PCOS is a complex, heterogeneous syndrome with reproductive, metabolic, inf= lammatory, mitochondrial, and psychological components. No single peptide t= reats PCOS. The mechanisms peptides influence happen to overlap meaningfull= y with the mechanisms PCOS depends on =E2=80=94 but the actual translation = from mechanism to clinical outcome in PCOS specifically is still mostly res= earch-stage. What we have strong evidence for GLP-1 receptor agonists genuinely help the metabolic side of PCOS and are n= ow part of mainstream care. The dual and triple incretin agonists (tirzepat= ide, retatrutide) are likely to outperform GLP-1 alone. What we have mechanistic plausibility for but limited PCOS-specific clinica= l data BPC-157 and KPV for gut-driven inflammation Kisspeptin modulators for HPO axis dysfunction MOTS-c, SS-31, and Urolithin A for ovarian mitochondrial dysfunction Thymosin Alpha-1 for the immune and inflammation piece What we don=E2=80=99t have Direct head-to-head PCOS clinical trials of most peptides Long-term safety data in this specific population Clear protocols for stacking these with conventional PCOS care Pregnancy safety data for most peptides (significant issue given fertility = goals) What this means practically: lifestyle modification, the metabolic medicati= ons (GLP-1 RAs increasingly central), and hormonal/antiandrogen approaches = are the proven foundation. Peptide research is a layer of mechanistic plaus= ibility on top of that foundation, not a replacement for it. Anyone framing= peptides as a PCOS =E2=80=9Ccure=E2=80=9D or =E2=80=9Cprimary treatment=E2= =80=9D is way out over their skis given the current evidence. The research is genuinely exciting. The clinical translation is still in pr= ogress. Final Thoughts PCOS is one of the most common conditions in women of reproductive age and = one of the most consequential across the lifespan. The mechanisms involved = =E2=80=94 insulin resistance, hyperandrogenism, chronic inflammation, mitoc= hondrial dysfunction, HPO axis dysregulation, gut barrier issues =E2=80=94 = happen to be exactly the kinds of mechanisms peptide research is good at ad= dressing. That=E2=80=99s not a coincidence. PCOS sits at the intersection of metaboli= c, inflammatory, and endocrine dysfunction. Any therapeutic class that targ= ets those layers will eventually have something to say about PCOS. The fact= that incretin peptides are already moving into mainstream PCOS care after = starting as diabetes drugs is a strong signal that this pattern will contin= ue. For anyone reading this who has PCOS or is supporting someone who does: the= foundational stuff still matters most. Lifestyle, sleep, exercise, stress = management, working with a clinician who actually understands PCOS. Convent= ional medications when needed. Peptide research is a layer to follow with i= nterest, not a replacement for working the basics. This is for research and educational purposes only. Nothing in this piece i= s medical advice. PCOS is a medical diagnosis. Work with a clinician. If this was useful, share it with someone you know who=E2=80=99s been navig= ating PCOS and feels like the standard playbook hasn=E2=80=99t fully explai= ned their experience =E2=80=94 and let me know in the comments what you=E2= =80=99d want me to break down next. =E2=80=94 Derek References Cleveland Clinic 2026 PCOS review (primary source) Sung N, Amir J, Abed Alwahab U, Falcone T. Polycystic ovary syndrome: An up= date on diagnosis and management. Cleveland Clinic Journal of Medicine. 202= 6;93(3):176-183. Full text [ https://substack.com/redirect/fdaf1708-28c9-49= 98-a293-986ccb60eae6?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p76= 8BWtuZifRB-Zs ] 2023 international evidence-based guideline Teede HJ, Tay CT, Laven J, et al. Recommendations from the 2023 internation= al evidence-based guideline for the assessment and management of polycystic= ovary syndrome. Fertil Steril. 2023;120(4):767-793. PubMed [ https://subst= ack.com/redirect/6575b4bc-a3cb-4c94-baa8-7de98f8dfb87?j=3DeyJ1IjoiNGl3b2U2I= n0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] PCOS pathophysiology (comprehensive review) Stener-Victorin E, Teede H, Norman RJ, et al. Polycystic ovary syndrome. Na= t Rev Dis Primers. 2024;10(1):27. PubMed [ https://substack.com/redirect/ba= bb04a6-9b52-4527-8f9c-606bb46b1cf4?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfda= mY0krRXGMy3p768BWtuZifRB-Zs ] GLP-1 receptor agonists in PCOS (2025 meta-analysis) Lin S, Deng Y, Huang J, et al. Efficacy and safety of GLP-1 receptor agonis= ts on weight management and metabolic parameters in PCOS women: a meta-anal= ysis of randomized controlled trials. Sci Rep. 2025;15(1):16512. PubMed [ h= ttps://substack.com/redirect/3102d403-818f-402c-9ee4-2db5468d1f20?j=3DeyJ1I= joiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] GLP-1, dual, and triple agonists in PCOS (2025 scoping review) The Effects of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on Polycys= tic Ovarian Syndrome: A Scoping Review. Cureus. 2025. Full text [ https://s= ubstack.com/redirect/43449217-f376-4861-a38e-9e1cbd27451b?j=3DeyJ1IjoiNGl3b= 2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] Kisspeptin improving ovarian insulin resistance (2026) Kisspeptin improves local ovarian insulin resistance in PCOS by modulating = the PI3K/AKT/GLUT4 signaling pathway. PLOS One. 2026. Full text [ https://s= ubstack.com/redirect/f3f54e39-5471-448f-9371-f7cafe79babd?j=3DeyJ1IjoiNGl3b= 2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] Kisspeptin and PCOS (HPO axis) Kisspeptin and Polycystic Ovary Syndrome. Front Endocrinol (Lausanne). Full= text [ https://substack.com/redirect/bd429ce9-c8a9-438a-8f41-db5802ce1aa5?= j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] Kisspeptin in granulosa cells (PI3K/AKT/ERK) Kisspeptin regulates the proliferation and apoptosis of ovary granulosa cel= ls in polycystic ovary syndrome by modulating the PI3K/AKT/ERK signalling p= athway. BMC Women=E2=80=99s Health. 2023. Full text [ https://substack.com/= redirect/ec9c11f6-afb1-4811-a296-0c92c1e8e57b?j=3DeyJ1IjoiNGl3b2U2In0.sVDxR= tmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] PCOS oxidative stress and mitochondrial dysfunction Zeber-Lubecka N, Ciebiera M, Hennig EE. Polycystic ovary syndrome and oxida= tive stress =E2=80=94 from bench to bedside. Int J Mol Sci. 2023;24(18):141= 26. Insulin resistance across tissues in PCOS Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ova= ry syndrome across various tissues: an updated review of pathogenesis, eval= uation, and treatment. J Ovarian Res. 2023;16(1):9. PCOS gut microbiome Rizk MG, Thackray VG. Intersection of polycystic ovary syndrome and the gut= microbiome. J Endocr Soc. 2020;5(2):bvaa177. BPC-157 gut-brain axis review Stable Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-= Brain Axis Function. Full text [ https://substack.com/redirect/7d9c4b14-536= d-4a70-b5be-5c1cae9df7a2?j=3DeyJ1IjoiNGl3b2U2In0.sVDxRtmZ85v8kfdamY0krRXGMy= 3p768BWtuZifRB-Zs ] MOTS-c in ovarian tissue Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression = by Attenuating USP7-Mediated LARS1 Deubiquitination. Full text [ https://su= bstack.com/redirect/b654156d-d27c-4861-abc5-1d7dead4f457?j=3DeyJ1IjoiNGl3b2= U2In0.sVDxRtmZ85v8kfdamY0krRXGMy3p768BWtuZifRB-Zs ] PCOS inflammation (low-grade) Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in th= e polycystic ovary syndrome. Mol Cell Endocrinol. 2011;335(1):30-41. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVOek0zTWpFeE1Td2lhV0YwSWpveE56YzROa= kF5TkRRNUxDSmxlSEFpT2pFNE1UQXhNemcwTkRrc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5LnhYaEhNbGMwVkw3QVhscE1YdzgxSzkzMHZ= pQVNMMHpUeFlhNFhGbXQ5ZGciLCJwIjoxOTczNzIxMTEsInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc4NjAyNDQ5LCJleHAiOjIwOTQxNzg0NDksImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.sy345H5gq2b48DMuY7WEisy8GgsLWbim42pJJca= K1Eo? --67e9e483af4652257f7d2fdc19d26f48cc109a9d336a8094dc3cdf175206 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable = PCOS: What It Actually Is, How It’s Managed Now, And The Peptide Mech= anisms Worth Watching=3D""
One of the most common conditions in women of = reproductive age — and one that happens to sit at the intersection of= every major mechanism peptide research targets.
͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­
Forwarded t= his email? Subscribe here for m= ore
=

PCOS: What It Actually Is, How It’s Managed Now, And The= Peptide Mechanisms Worth Watching

Dere= k
May 12
 
<= tr>
3D""
3D""
3D""
3D""
READ IN APP<= img class=3D"icon text-icon" src=3D"https://substackcdn.com/image/fetch/$s_= !ET-_!,w_36,c_scale,f_png,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsu= bstack.com%2Ficon%2FLucideArrowUpRight%3Fv%3D4%26height%3D36%26fill%3Dnone%= 26stroke%3D%2523808080%26strokeWidth%3D2" width=3D"18" height=3D"18" style= =3D"min-width: 18px;min-height: 18px;border: none;vertical-align: middle;ma= rgin-right: 0;margin-left: 0;max-width: 18px" alt=3D"">
&nb= sp;

One of the most common conditions in women of reproductive age — = and one that happens to sit at the intersection of every major mechanism pe= ptide research targets.

Research and educational purpo= ses only. Nothing in this piece is medical advice. PCOS is a medical diagno= sis that requires real clinical care — peptides discussed here are re= search tools, not treatments. If you have PCOS or suspect you do, work with= a clinician.

What PCOS Actually Is

Let’s start with the basics.

Polycys= tic ovary syndrome (PCOS) is the most common hormonal disord= er in women of reproductive age — affecting roughly 10 to 13 percent = of women globally. It’s not a single disease with a single cause. It&= #8217;s a complex, heterogeneous syndrome where three things tend to show u= p together:

  • Irregular or absent ovulation<= /strong>, which leads to irregular periods and fertility issues

  • Hyperan= drogenism — excess androgens, the “male” h= ormones like testosterone. This is what drives the cosmetic stuff: acne, hi= rsutism (unwanted hair growth in male-pattern areas), and androgenic hair l= oss

  • Polycystic ovarian morphology — multiple small folli= cles on ultrasound, or elevated anti-Müllerian hormone (AMH)

3D""
Upgrade to pa= id

But the real story is bigger than the= ovaries.

PCOS is fundamentally a wh= ole-body metabolic and endocrine condition. Most patients also have insulin= resistance, chronic low-grade inflammation, increased risk of type 2 diabe= tes, obesity, sleep apnea, cardiovascular disease, anxiety, depression, and= endometrial cancer.

It’s lifelong. The = reproductive symptoms get most of the attention, but the metabolic and psyc= hological consequences extend well past the reproductive years.

What Drives PCOS

There are a few intercon= nected things going wrong at once. Understanding these matters because ever= y peptide mechanism we’ll discuss later targets one of them.

Genetics. There’s a strong hereditary = component. In one study of first-degree relatives, 24 percent of mothers an= d 32 percent of sisters of PCOS patients also had PCOS. Genome-wide associa= tion studies have identified multiple risk genes involved in gonadotropin a= ction, insulin signaling, and androgen biosynthesis. Interestingly, male re= latives can show metabolic features of PCOS too — early-onset male-pa= ttern baldness, insulin resistance, type 2 diabetes — suggesting this= is a systemic genetic risk, not just ovary-specific.

Ovarian hyperandrogenism. This is the core issue. About 90 percent of PCOS patients hav= e it. The theca cells in the ovary make too much androgen, which disrupts f= ollicle maturation. Instead of one follicle maturing each cycle and releasi= ng an egg, multiple small follicles arrest at an immature stage. That’= ;s the “polycystic” appearance on ultrasound — they aren&= #8217;t cysts in the disease sense, they’re stalled follicles.=

Insulin resistance and hyperinsulinemia.<= span> Insulin resistance is present in a majority of PCOS patients — = even in lean ones, which surprises a lot of people. When cells stop respond= ing properly to insulin, the pancreas pumps out more to compensate. That el= evated insulin does two damaging things in PCOS:

  • I= t directly stimulates the ovaries to make more androgens

  • It suppresses the liver’s pr= oduction of sex hormone-binding globulin (SHBG), which means more free test= osterone is floating around unbound

This is why f= ixing insulin resistance is one of the most important targets in PCOS care.=

HPO axis dysfunction. The hypothala= mic-pituitary-ovarian axis runs the show on the hormonal side. In PCOS, gon= adotropin-releasing hormone (GnRH) pulses too fast, which skews luteinizing= hormone (LH) higher than follicle-stimulating hormone (FSH). That LH/FSH i= mbalance further drives ovarian androgen production and impairs ovulation.<= /span>

Chronic low-grade inflammation. Adipose tissue — especially visceral fat — in PCOS pumps out= inflammatory cytokines: TNF-alpha, IL-6, IL-1-beta. The gut microbiome is = also altered, with increased intestinal permeability contributing to system= ic inflammation. That inflammation worsens insulin resistance, increases ov= arian androgen production, and impairs follicle development. It&= #8217;s a feedback loop.

Mitochondrial dysfunc= tion. This is newer to the conversation but increasingly wel= l-documented. Granulosa cells (the cells supporting the egg) in PCOS show i= mpaired mitochondrial function, elevated reactive oxygen species, and reduc= ed mitochondrial membrane potential. That energy failure in the ovary contr= ibutes to follicle arrest and egg quality issues.

How PCOS Is Currently Managed

This is the conven= tional medicine approach, based on the 2023 international evidence-based gu= ideline. Knowing this matters because it’s the foundation that peptid= e research is being layered onto.

Lifestyle modific= ation. Always first-line, always non-negotiable. Diet (no si= ngle “best” diet — sustainable, individualized matters mo= re than the specific approach), 150-300 minutes of moderate exercise per we= ek plus muscle-strengthening on two days, sleep, stress management. Even mo= dest weight loss (5-10 percent of body weight) can dramatically improve sym= ptoms and restore ovulation in some patients.

Hormonal contraceptives. Combined oral contraceptives are = first-line for managing menstrual irregularities and androgen-driven sympto= ms like acne and hirsutism. They protect the uterine lining from the cancer= risk of unopposed estrogen, regulate cycles, and reduce androgens. Formula= tions with antiandrogenic progestins (drospirenone, dienogest) are preferre= d when hyperandrogenism is prominent.

Spiron= olactone. An antiandrogen often added when oral contraceptiv= es alone don’t control hirsutism or acne. Dosing typically 50-200 mg/= day. Has fetal toxicity risk, so contraception is required.

Metformin. The old workhorse. It improves in= sulin sensitivity. The current guideline has cooled on metformin somewhat &= #8212; it’s not first-line for weight loss or ovulation induction any= more, though it still has a role in adolescents and lean patients with pred= iabetes or type 2 diabetes. Maximum dose 2000 mg/day, extended-release pref= erred for tolerability.

GLP-1 receptor agoni= sts. This is where the field is shifting fast. Liraglutide, = semaglutide, and exenatide are increasingly used off-label in PCOS. A 2025 = meta-analysis showed GLP-1 RAs significantly reduce fasting insulin, post-g= lucose insulin response, and insulin resistance scores, plus they drive mea= ningful weight loss. Their mechanism hits multiple PCOS drivers at once = 212; improving insulin sensitivity, reducing inflammation, and indirectly r= educing ovarian androgen production. Critical note: pregnancy sa= fety data is lacking, so effective contraception is required for women of r= eproductive age.

Inositol. Spec= ifically myo-inositol and D-chiro-inositol in research. It’s a second= messenger that helps insulin signaling and FSH signaling at the cellular l= evel. The evidence is modest — possible improvement in metabolic meas= ures, but limited effects on ovulation or hirsutism. Low risk of harm, so i= t shows up frequently as an adjunct.

Letrozo= le. The first-line ovulation induction drug now (it overtook= clomiphene). For PCOS patients trying to conceive who don’t ovulate = on their own, letrozole started day 3 of cycle, 2.5 mg titrated up to 7.5 m= g as needed.

Bariatric surgery. For PCOS patients with severe obesity who haven’t responded to oth= er interventions. Often produces dramatic improvements in insulin resistanc= e, androgens, and ovulation.

What’s missing fr= om this picture:

There’s no tr= eatment that addresses the root genetic and epigenetic drivers, no targeted= way to fix ovarian mitochondrial dysfunction, no clean solution for the ch= ronic inflammation piece, and limited tools for the psychological burden.

This is where peptide research gets interesting= =2E

Why PCOS Is A Peptide Research Target

Here’s why this matters from a peptide research standpoint.=

The PCOS phenotype involves several mechanisms that overla= p directly with what peptides are known to influence: insulin sensitivity, = chronic inflammation, gut barrier integrity, mitochondrial function, HPO ax= is signaling, and tissue repair. Almost every layer of PCOS pathophysiology= has a peptide mechanism that’s been studied for it in some context.<= /p>

That’s not a claim that any peptide treats PCOS. The = point is that the mechanisms PCOS depends on aren’t black boxes ̵= 2; they’re well-mapped pathways, and several peptides have research b= acking for influencing those exact pathways.

Let’s wa= lk through them.

GLP-1 And Advanced Incretins

This is the most clinically advanced and best-evidenced pep= tide class for PCOS, so we’ll start here.

GLP= -1 receptor agonists (semaglutide, liraglutide, exenatide). = Discussed above as part of standard care. The mechanism in PCOS hits three = pillars at once: weight loss (reduces adipose-driven inflammation and impro= ves insulin sensitivity systemically), improved insulin sensitivity (lowers= compensatory hyperinsulinemia, which is what’s driving ovarian andro= gen production), and direct anti-inflammatory effects on multiple tissues.<= /span>

GLP-1/GIP dual agonists (tirzepatide). Tirzepatide adds GIP receptor agonism on top of GLP-1. In PCOS re= search and metabolic syndrome research more broadly, the addition of GIP si= gnaling produces greater improvements in insulin sensitivity and weight los= s compared to GLP-1 alone. The mechanism: GIP signaling enhances insulin se= nsitivity in adipose tissue and improves the metabolic flexibility of fat c= ells.

GLP-1/GIP/glucagon triple agonist (ret= atrutide). Retatrutide adds glucagon receptor agonism —= ; which, somewhat counterintuitively, increases energy expenditure and acce= lerates fat breakdown for fuel. In a 2025 scoping review, the triple agonis= t class produced the largest improvements in weight loss and insulin sensit= ivity in PCOS-relevant research compared to GLP-1 and dual agonists. Retatr= utide is still pre-FDA approval but is moving through trials.

What the literature shows specifically for PCOS

<= ul style=3D"margin-top: 0;padding: 0;">

  • Significant reductions in fasting insulin and post-glucose in= sulin response

  • Si= gnificant improvements in insulin resistance scores (HOMA-IR)

  • Improvements in dysmenorrhea a= nd ovarian morphology in some studies

  • Weight loss substantially greater than with metformin<= /p>

    • What the literature shows is NOT chan= ged by GLP-1 RAs alone

    • Total and free testosterone (most= ly unchanged in meta-analysis)

    • DHEA-S, SHBG, free androgen index

    • Hirsutism scores (modest at best)

      • The honest interpretation: GLP-1 RAs are powerful too= ls for the metabolic side of PCOS, but they don’t fully reverse the i= ntrinsic ovarian hyperandrogenism. That confirms PCOS is fundame= ntally an ovarian disorder exacerbated by metabolic dysfunction — not= the other way around. Weight loss alone doesn’t fix every= thing, but it dramatically improves a lot of it.

      BPC-157 And The Gut-Ovary Connection

      This is one = of the more underrated angles in PCOS peptide research.

      The= gut microbiome is altered in PCOS. There’s reduced microbial diversi= ty, increased intestinal permeability (”leaky gut”), and this i= s part of what drives systemic inflammation. That chronic low-grade inflamm= ation worsens insulin resistance and ovarian androgen production. Fix the g= ut, and you address one of the upstream amplifiers.

      BPC-157 (Body Protection Compound). A pentadecapeptide orig= inally derived from gastric juice. The mechanism is multimodal: it promotes= gut lining repair, reduces intestinal permeability, modulates the gut-brai= n axis, supports angiogenesis, and has anti-inflammatory effects. In animal= research, BPC-157 has reversed leaky gut syndrome and restored multiple de= ranged molecular pathways. It’s also been shown to influence dopamine= rgic signaling, GABA activity, and serotonergic pathways — which is r= elevant to the psychological symptoms in PCOS (anxiety, depression).=

      Why this matters for PCOS:

      • =

        Gut barrier r= epair reduces endotoxin leakage and systemic inflammation, which improves i= nsulin sensitivity

      • The angioge= nic and tissue repair properties may support ovarian tissue health

        • =

      This is not a “BPC-157 treats PCOS” cla= im. It’s a “the upstream amplifier of inflammation i= n PCOS partially originates in the gut, and BPC-157 has research evidence f= or restoring gut barrier function” claim.

      KPV (lysine-proline-valine). A C-terminal tri= peptide derived from alpha-MSH. Potent anti-inflammatory, immune-modulating= , and antimicrobial activity, particularly in the gut and skin. KPV suppres= ses inflammatory cytokines (TNF-alpha, IL-6) which are the same cytokines e= levated in PCOS adipose tissue. Often stacked with BPC-157 for gut-focused = protocols. Relevant for the inflammation arm of PCOS.

      Kisspeptin And The HPO Axis

      This is one of= the most directly relevant peptide research areas for PCOS, and it gets ve= ry little attention in mainstream peptide communities.

      Kiss= peptin is a hypothalamic peptide encoded by the KISS1 gene. It’s the = master regulator of GnRH neurons — meaning it’s upstream of the= entire reproductive hormone cascade. Without kisspeptin signaling, GnRH do= esn’t pulse, LH and FSH don’t release properly, and the ovaries= don’t function.

      In PCOS, kisspeptin signaling is dys= regulated. Higher kisspeptin tone contributes to the increased LH pulse fre= quency that drives ovarian androgen production. But here’s where it g= ets interesting:

      Research published = in 2024-2026 has shown that kisspeptin, particularly in local ovarian tissu= e, plays a different role from its central role — it improves local o= varian insulin resistance and protects mitochondrial function in granulosa = cells.

      What the recent research shows:

      • Kisspeptin activates the PI3K/AKT/GLUT4 signaling pathway in ova= rian granulosa cells, improving local insulin sensitivity

      • Kisspeptin reduces reactive oxygen= species in granulosa cells and increases mitochondrial membrane potential = — protecting energy production in the cells that support egg developm= ent

      • =

        Antagonizing = kisspeptin signaling worsens these parameters

      This is a fascinating duality: central (hypothalamic) kisspep= tin dysregulation drives parts of PCOS pathology, but peripheral (ovarian) = kisspeptin appears to be protective. The therapeutic implication= is complex — you can’t just turn kisspeptin up or down systemi= cally. But it points to kisspeptin signaling as a major research target, an= d selective modulators may be a future direction.

      Fo= r the curious: there are already kisspeptin antagonists being developed for= hyperandrogenism and selective agonists being studied for hypogonadism. PC= OS is in between, and the research is genuinely active.

      Mitochondrial Peptides

      Mitochondrial dysfunction = in ovarian granulosa cells is one of the more recent additions to the PCOS = pathophysiology picture, and it opens up a different category of peptide re= search.

      MOTS-c. A mitochondria-deriv= ed 16-amino acid peptide encoded by mitochondrial 12S rRNA. It improves ins= ulin sensitivity, increases mitochondrial efficiency, and modulates metabol= ic signaling through AMPK activation. MOTS-c has been studied for metabolic= syndrome and aging-related metabolic decline. There’s preliminary re= search suggesting reduced MOTS-c levels in ovarian tissue may be relevant t= o PCOS pathology, though direct PCOS clinical work is still early.

      The connection: PCOS granulosa cells show impaired mitochond= rial function. MOTS-c’s mechanism of restoring mitochondrial signalin= g and improving systemic insulin sensitivity overlaps directly with two maj= or PCOS drivers.

      SS-31 (elamipretide). A mitochondrial membrane-stabilizing peptide that binds cardiolipin. SS-= 31 protects mitochondria from oxidative damage and restores ATP production.= While it hasn’t been formally studied in PCOS, the rationale is stra= ightforward — PCOS granulosa cells have damaged mitochondria with red= uced membrane potential and elevated ROS, and SS-31 is one of the most dire= ct tools for that exact problem. Research models in oocyte aging (which sha= res some features with PCOS-related egg quality issues) have shown SS-31 im= proves oocyte quality.

      Urolithin A.= A postbiotic mitophagy inducer. UA promotes the clearance of damaged= mitochondria and the building of new ones. There’s emerging research= suggesting that mitophagy dysfunction in granulosa cells contributes to PC= OS, and UA’s mechanism of restoring mitophagy is mechanistically rele= vant.

      None of these have completed PCOS-specific hum= an trials. But mechanistically, the mitochondrial peptide class is one of t= he more compelling research directions for the ovarian and metabolic dysfun= ction in PCOS.

      Other Peptides Worth Knowing Abo= ut

      A few additional peptides with mechanisms that touch PC= OS pathophysiology.

      Thymosin Alpha-1. Immune-modulating peptide. PCOS involves chronic low-grade inflammation a= nd skewed immune signaling. While not a direct PCOS therapy, the immune mod= ulation may be relevant to the inflammation arm.

      GHK-Cu. Tripeptide-copper complex with anti-inflammator= y, antioxidant, and tissue repair effects. Skin-relevant applications conne= ct to the cosmetic burden of PCOS (acne, hyperpigmentation, hair-related is= sues).

      Selank and Semax. Russ= ian-developed cognitive peptides with anxiolytic and BDNF-modulating effect= s respectively. PCOS has high prevalence of anxiety and depression. These d= on’t address the underlying PCOS biology but may have relevance for t= he psychological burden.

      Tesofensine. Not a peptide, but worth flagging — it’s a triple mono= amine reuptake inhibitor in development for obesity that’s showing st= rong weight loss data and may be relevant for PCOS patients who don’t= tolerate GLP-1 agonists.

      The Honest Bi= g Picture

      I want to be direct about what this all adds up = to.

      PCOS is a complex, heterogeneous syndrome with re= productive, metabolic, inflammatory, mitochondrial, and psychological compo= nents. No single peptide treats PCOS. The mechanisms = peptides influence happen to overlap meaningfully with the mechanisms PCOS = depends on — but the actual translation from mechanism to clinical ou= tcome in PCOS specifically is still mostly research-stage.

      What we have strong evidence for

      GLP-1 = receptor agonists genuinely help the metabolic side of PCOS and are now par= t of mainstream care. The dual and triple incretin agonists (tirzepatide, r= etatrutide) are likely to outperform GLP-1 alone.

      What we have mechanistic plausibility for but limited PCOS-specific clin= ical data

      • BPC-157 and KPV for gut-driven inflammation

      • Kisspeptin modulato= rs for HPO axis dysfunction

      • MOTS-c, SS-31, and Urolithin A for ovarian mitochondrial dysfunc= tion

      • Thymosin Alp= ha-1 for the immune and inflammation piece

      What we don’t have

        =

      • Direct head-to-head PCOS = clinical trials of most peptides

      • Long-term safety data in this specific population

        • <= li style=3D"margin: 8px 0 0 32px;mso-special-format: bullet;">

        Clear protocols for stacki= ng these with conventional PCOS care

      • Pregnancy safety data for most peptides (significant is= sue given fertility goals)

      What this means = practically: lifestyle modification, the metabolic medications (GLP-1 RAs i= ncreasingly central), and hormonal/antiandrogen approaches are the proven f= oundation. Peptide research is a layer of mechanistic plausibility on top o= f that foundation, not a replacement for it. Anyone framing pept= ides as a PCOS “cure” or “primary treatment” is way= out over their skis given the current evidence.

      The r= esearch is genuinely exciting. The clinical translation is still in progres= s.

      Final Thoughts

      PCOS is one = of the most common conditions in women of reproductive age and one of the m= ost consequential across the lifespan. The mechanisms involved — insu= lin resistance, hyperandrogenism, chronic inflammation, mitochondrial dysfu= nction, HPO axis dysregulation, gut barrier issues — happen to be exa= ctly the kinds of mechanisms peptide research is good at addressing.

      That’s not a coincidence. PCOS sits at the intersection of = metabolic, inflammatory, and endocrine dysfunction. Any therapeutic class t= hat targets those layers will eventually have something to say about PCOS. = The fact that incretin peptides are already moving into mainstream PCOS car= e after starting as diabetes drugs is a strong signal that this pattern wil= l continue.

      For anyone reading this who has PCOS or is supp= orting someone who does: the foundational stuff still matters most. Lifesty= le, sleep, exercise, stress management, working with a clinician who actual= ly understands PCOS. Conventional medications when needed. Peptide research= is a layer to follow with interest, not a replacement for working the basi= cs.

      This is for research and educational purposes only.= Nothing in this piece is medical advice. PCOS is a medical diagnosis. Work= with a clinician.

      If this was useful, share it with s= omeone you know who’s been navigating PCOS and feels like the standar= d playbook hasn’t fully explained their experience — and let me= know in the comments what you’d want me to break down next.

      — Derek

      =

      References

      Cleveland Clinic 2026 PCOS review (primary source)

      Sung N, Amir J, Abed Alwahab U, Falcone T. Polyc= ystic ovary syndrome: An update on diagnosis and management. Cle= veland Clinic Journal of Medicine. 2026;93(3):176-183. Full text

      2023 = international evidence-based guideline

      Teede= HJ, Tay CT, Laven J, et al. Recommendations from the 2023 inter= national evidence-based guideline for the assessment and management of poly= cystic ovary syndrome. Fertil Steril. 2023;120(4):767-793. PubMed

      <= strong>PCOS pathophysiology (comprehensive review)

      Stener-Victorin E, Teede H, Norman RJ, et al. Polycystic = ovary syndrome. Nat Rev Dis Primers. 2024;10(1):27. PubMed

      GLP-1 receptor agonists in PCOS (2025 meta-analysis)

      Lin S, Deng Y, Huang J, et al. Efficacy and safety o= f GLP-1 receptor agonists on weight management and metabolic parameters in = PCOS women: a meta-analysis of randomized controlled trials. Sci= Rep. 2025;15(1):16512. PubMed

      GLP-1, dual, and triple agonists in PCO= S (2025 scoping review)

      The Effects of Glucago= n-Like Peptide-1 (GLP-1) Receptor Agonists on Polycystic Ovarian Syndrome: = A Scoping Review. Cureus. 2025. Full text

      Kisspeptin improv= ing ovarian insulin resistance (2026)

      Kisspept= in improves local ovarian insulin resistance in PCOS by modulating the PI3K= /AKT/GLUT4 signaling pathway. PLOS One. 2026. Full text

      Kis= speptin and PCOS (HPO axis)

      Kisspeptin and Pol= ycystic Ovary Syndrome. Front Endocrinol (Lausanne). Full text

      Kisspeptin in granulosa cells (PI3K/AKT/ERK)

      Kisspeptin regulates the proliferation and apoptosis of ovary granulos= a cells in polycystic ovary syndrome by modulating the PI3K/AKT/ERK signall= ing pathway. BMC Women’s Health. 2023. Full text

      PCOS= oxidative stress and mitochondrial dysfunction

      Zeber-Lubecka N, Ciebiera M, Hennig EE. Polycystic ovary syn= drome and oxidative stress — from bench to bedside. Int J = Mol Sci. 2023;24(18):14126.

      Insulin resistan= ce across tissues in PCOS

      Zhao H, Zhang J, C= heng X, Nie X, He B. Insulin resistance in polycystic ovary synd= rome across various tissues: an updated review of pathogenesis, evaluation,= and treatment. J Ovarian Res. 2023;16(1):9.

      PCOS gut microbiome

      Rizk MG, Th= ackray VG. Intersection of polycystic ovary syndrome and the gut= microbiome. J Endocr Soc. 2020;5(2):bvaa177.

      BPC-157 gut-brain axis review

      Sta= ble Gastric Pentadecapeptide BPC 157 May Recover Brain-Gut Axis and Gut-Bra= in Axis Function. Full text

      MOTS-c in ovarian tissue

      Mitochondrial-Derived Peptide MOTS-c Suppresses Ovar= ian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination.= Full text

      PCOS inflammation (low-grade)

      Repaci A, Gambineri A, Pasquali R. The role of low-= grade inflammation in the polycystic ovary syndrome. Mol Cell En= docrinol. 2011;335(1):30-41.

    You're currently a free subscriber to Research Radar. For the full experience, upgrade your subscription.

    Upg= rade to paid

     
    3D""Share<= /a>
     
     
    <= /tbody>
    =
    3D""Like
    3D""Comment
    3D""Restack
    		=
     

    © 2026 Derek Pruski
    548 Market Street PMB 7= 2296, San Francisco, CA 94104
    Unsubscribe

    3D"=

    3D""3D""= --67e9e483af4652257f7d2fdc19d26f48cc109a9d336a8094dc3cdf175206--